These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37127479)

  • 21. A pan-kidney cancer study identifies subtype specific perturbations on pathways with potential drivers in renal cell carcinoma.
    Zhan X; Liu Y; Yu CY; Wang TF; Zhang J; Ni D; Huang K
    BMC Med Genomics; 2020 Dec; 13(Suppl 11):190. PubMed ID: 33371886
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials.
    de Velasco G; McKay RR; Lin X; Moreira RB; Simantov R; Choueiri TK
    Clin Genitourin Cancer; 2017 Dec; 15(6):652-660.e1. PubMed ID: 28410911
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytoplasmic expression of Twist1, an EMT-related transcription factor, is associated with higher grades renal cell carcinomas and worse progression-free survival in clear cell renal cell carcinoma.
    Rasti A; Madjd Z; Abolhasani M; Mehrazma M; Janani L; Saeednejad Zanjani L; Asgari M
    Clin Exp Med; 2018 May; 18(2):177-190. PubMed ID: 29204790
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Percutaneous radiofrequency ablation for renal cell carcinoma vs. partial nephrectomy: Comparison of long-term oncologic outcomes in both clear cell and non-clear cell of the most common subtype.
    Liu N; Huang D; Cheng X; Chong Y; Wang W; Gan W; Guo H
    Urol Oncol; 2017 Aug; 35(8):530.e1-530.e6. PubMed ID: 28408296
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does chromophobe renal cell carcinoma have better survival than clear cell renal cell carcinoma? A clinical-based cohort study and meta-analysis.
    Jiang HM; Wei JH; Zhang ZL; Fang Y; Zhou BF; Chen ZH; Lu J; Liao B; Zhou FJ; Luo JH; Chen W
    Int Urol Nephrol; 2016 Feb; 48(2):191-9. PubMed ID: 26589610
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Protective Role for Androgen Receptor in Clear Cell Renal Cell Carcinoma Based on Mining TCGA Data.
    Zhao H; Leppert JT; Peehl DM
    PLoS One; 2016; 11(1):e0146505. PubMed ID: 26814892
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic and diagnostic implications of epithelial cell adhesion/activating molecule (EpCAM) expression in renal tumours: a retrospective clinicopathological study of 948 cases using tissue microarrays.
    Zimpfer A; Maruschke M; Rehn S; Kundt G; Litzenberger A; Dammert F; Zettl H; Stephan C; Hakenberg OW; Erbersdobler A
    BJU Int; 2014 Aug; 114(2):296-302. PubMed ID: 24215118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. LZTS2: A novel and independent prognostic biomarker for clear cell renal cell carcinoma.
    Peng Y; Greenland NY; Lang UE; Stohr BA
    Pathol Res Pract; 2022 Apr; 232():153831. PubMed ID: 35287088
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MicroRNA-194 is a Marker for Good Prognosis in Clear Cell Renal Cell Carcinoma.
    Nofech-Mozes R; Khella HW; Scorilas A; Youssef L; Krylov SN; Lianidou E; Sidiropoulos KG; Gabril M; Evans A; Yousef GM
    Cancer Med; 2016 Apr; 5(4):656-64. PubMed ID: 26860079
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 2018 Leibovich prognostic model for renal cell carcinoma: Performance in a large population with special consideration of Black race.
    Schmeusser BN; Patil DH; Nicaise EH; Armas-Phan M; Nabavizadeh R; Narayan VM; Joshi SS; Ogan K; Osunkoya AO; Bilen MA; Master VA
    Cancer; 2024 Feb; 130(3):453-466. PubMed ID: 37803521
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chromophobe Renal Cell Carcinoma: Results From a Large Single-Institution Series.
    Casuscelli J; Becerra MF; Seier K; Manley BJ; Benfante N; Redzematovic A; Stief CG; Hsieh JJ; Tickoo SK; Reuter VE; Coleman JA; Russo P; Ostrovnaya I; Hakimi AA
    Clin Genitourin Cancer; 2019 Oct; 17(5):373-379.e4. PubMed ID: 31326335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DYSF expression in clear cell renal cell carcinoma: A retrospective study of 2 independent cohorts.
    Ha M; Jeong H; Roh JS; Lee B; Han ME; Oh SO; Sohn DH; Kim YH
    Urol Oncol; 2019 Oct; 37(10):735-741. PubMed ID: 31377166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distinct immunophenotypes and prognostic factors in renal cell carcinoma with sarcomatoid differentiation: a systematic study of 19 immunohistochemical markers in 42 cases.
    Yu W; Wang Y; Jiang Y; Zhang W; Li Y
    BMC Cancer; 2017 Apr; 17(1):293. PubMed ID: 28449664
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative real-world survival outcomes of metastatic papillary and clear cell renal cell carcinoma treated with immunotherapy, targeted therapy, and combination therapy.
    Riveros C; Ranganathan S; Xu J; Chang C; Kaushik D; Morgan M; Miles BJ; Muhammad T; Anis M; Aghazadeh M; Zhang J; Efstathiou E; Klaassen Z; Brooks MA; Rini B; Wallis CJD; Satkunasivam R
    Urol Oncol; 2023 Mar; 41(3):150.e1-150.e9. PubMed ID: 36610815
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Incidence and long-term prognosis of papillary renal cancer. Results of a retrospective multicenter study].
    Waalkes S; Roos FC; Eggers H; Schumacher S; Janssen M; Wegener G; Thüroff JW; Hofmann R; Schrader M; Kuczyk MA; Schrader AJ;
    Urologe A; 2011 Sep; 50(9):1125-9. PubMed ID: 21845424
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ESM-1 Mediates Cell Progression in Clear Cell Renal Cell Carcinoma by Affecting Wnt/β-Catenin Signalling Pathway.
    Liu X; Wang F; Du W; Yang X
    Arch Esp Urol; 2023 Jun; 76(4):290-297. PubMed ID: 37455528
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of CD105 cancer stem cell marker in three subtypes of renal cell carcinoma.
    Saeednejad Zanjani L; Madjd Z; Abolhasani M; Shariftabrizi A; Rasti A; Asgari M
    Cancer Biomark; 2018; 21(4):821-837. PubMed ID: 29286924
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma.
    Beck SD; Patel MI; Snyder ME; Kattan MW; Motzer RJ; Reuter VE; Russo P
    Ann Surg Oncol; 2004 Jan; 11(1):71-7. PubMed ID: 14699037
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor grade estımatıon of clear cell and papıllary renal cell carcınomas usıng contrast-enhanced MDCT and FSE T2 weıghted MR ımagıng: radıology-pathology correlatıon.
    Halefoglu AM; Ozagari AA
    Radiol Med; 2021 Sep; 126(9):1139-1148. PubMed ID: 34100169
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of survival outcomes in patients with metastatic papillary vs. clear-cell renal cell carcinoma: a propensity-score analysis.
    Rosiello G; Palumbo C; Knipper S; Pecoraro A; Luzzago S; St-Hilaire PA; Tian Z; Capitanio U; Montorsi F; Shariat SF; Saad F; Briganti A; Karakiewicz PI
    World J Urol; 2021 Feb; 39(2):461-472. PubMed ID: 32253579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.